NeoGenomics — Third Quarter 2026 Earnings Summary

NeoGenomics reported third-quarter 2026 total revenue of $209 million, representing an 11% year-over-year increase driven by a 13% growth in clinical services and a 29% surge in next-generation sequencing revenue. The company expanded its GAAP gross margin to 46% and reduced its net loss to $8 million, while delivering adjusted EBITDA of $19 million. Leadership succession was announced, with Warren Stone set to become CEO in January 2027, replacing current CEO Tony Zook who will transition to Executive Chairman. Additionally, NeoGenomics raised its full-year 2026 revenue guidance to a range of $807 million to $809 million and adjusted EBITDA guidance to approximately $60 million.